Mabwell (Shanghai) Bioscience Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06692166
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06592326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06492005
Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06389942
- Locations
- 🇨🇳
PKUcare Luzhong Hospital, Zibo, Shandong, China
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06196736
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- Conditions
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06175351
- Locations
- 🇨🇳
Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia), Baotou, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, China
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06079112
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 281
- Registration Number
- NCT06008366
- Locations
- 🇨🇳
Ethics Committee of Fudan University Shanghai Cancer Center, Shanghai, 上海市, China
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT06008379
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The Lung Cancer Center of Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 261
- Registration Number
- NCT05990452
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Centel, Shanghai, China